CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 817 enrolled
Drug / intervention
HPV vaccine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02994290
NCT02994290N/ACompleted

Evaluation of the Implementation and Effectiveness of a Pilot Quality Improvement Program to Increase HPV Vaccine Uptake: Inpatient Postpartum HPV Immunization (IPP-HPV) Program

Yale University·interventional·Posted Dec 15, 2016·Updated Jan 9, 2023

In Brief

A clinical study evaluating HPV vaccine and Inpatient Postpartum HPV Immunization Quality Improvement Program for HPV Vaccination. Completed, enrolled 817 participants across 1 site.

Detailed Summary

The purpose of the proposed pilot study is to assess the implementation of IPP-HPV immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and facilitators of this intervention to optimize its feasibility and effectiveness. It is imperative that innovative interventions be developed to achieve comprehensive utilization of this highly effective vaccine to reduce rates of HPV infection, lower rates of cervical and other HPV associated cancers, and address cancer disparities.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHPV Vaccination
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 15, 2016
Enrollment StartJan 1, 2017
Primary CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.5 years ago

Interventions

HPV vaccinedrug

After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.

Inpatient Postpartum HPV Immunization Quality Improvement Programbehavioral

The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses. Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women. All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed.